Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Deals

UB Biotechnology Secures Series A Funding for Flow Cytometry Platform

Fineline Cube Nov 22, 2022

China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens...

Company Deals

IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform

Fineline Cube Nov 22, 2022

China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...

Policy / Regulatory

Shanghai Unveils Policies to Boost Global Biomedical R&D Hub

Fineline Cube Nov 22, 2022

The Shanghai municipal government has released a set of policies and measures aimed at accelerating...

Company

WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai

Fineline Cube Nov 22, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...

Company Deals

Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics

Fineline Cube Nov 22, 2022

Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...

Company Drug

Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China

Fineline Cube Nov 22, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing...

Company Drug

Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors

Fineline Cube Nov 22, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...

Company Drug

Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy

Fineline Cube Nov 22, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...

Company Drug

Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP

Fineline Cube Nov 22, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...

Company Deals

JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration

Fineline Cube Nov 22, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership...

Company Drug

Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications

Fineline Cube Nov 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...

Company Drug

Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic

Fineline Cube Nov 22, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...

Company Drug

Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong

Fineline Cube Nov 21, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...

Company Drug

IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD

Fineline Cube Nov 21, 2022

China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...

Company Deals Medical Device

ViVest Medical Raises Funds for Wearable Cardioverter Defibrillator Development

Fineline Cube Nov 21, 2022

Suzhou-based device maker ViVest Medical Technology Co., Ltd has reportedly raised “hundreds of millions” of...

Company Drug

Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera

Fineline Cube Nov 21, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...

Policy / Regulatory

China’s CDE, HNMPA, and Bo’ao Lecheng Release Real-world Drug Research Measures

Fineline Cube Nov 21, 2022

The Center for Drug Evaluation (CDE), Hainan Medical Products Administration (HNMPA), and Bo’Ao Lecheng Medical...

Company Medical Device

Hotgen Biotech Receives FDA EUA for COVID-19 Antigen Home Test

Fineline Cube Nov 21, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving Emergency Use Authorization (EUA) from...

Company Deals

Wolters Kluwer Partners with China’s NCID to Advance Infectious Disease Diagnosis

Fineline Cube Nov 21, 2022

Holland-based information and software solutions provider Wolters Kluwer has announced a partnership with China’s National...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches New VBP Tender

Fineline Cube Nov 21, 2022

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...

Posts pagination

1 … 600 601 602 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.